Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection - PubMed (original) (raw)
. 2012 Jan 1;302(1):H299-311.
doi: 10.1152/ajpheart.00723.2011. Epub 2011 Oct 14.
Affiliations
- PMID: 22003054
- DOI: 10.1152/ajpheart.00723.2011
Free article
Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
Tong Zhang et al. Am J Physiol Heart Circ Physiol. 2012.
Free article
Abstract
The Mas receptor is a class I G-protein-coupled receptor that is expressed in brain, testis, heart, and kidney. The intracellular signaling pathways activated downstream of Mas are still largely unknown. In the present study, we examined the expression pattern and signaling of Mas in the heart and assessed the participation of Mas in cardiac ischemia-reperfusion injury. Mas mRNA and protein were present in all chambers of human hearts, with cardiomyocytes and coronary arteries being sites of enriched expression. Expression of Mas in either HEK293 cells or cardiac myocytes resulted in constitutive coupling to the G(q) protein, which in turn activated phospholipase C and caused inositol phosphate accumulation. To generate chemical tools for use in probing the function of Mas, we performed a library screen and chemistry optimization program to identify potent and selective nonpeptide agonists and inverse agonists. Mas agonists activated G(q) signaling in a dose-dependent manner and reduced coronary blood flow in isolated mouse and rat hearts. Conversely, treatment of isolated rat hearts with Mas inverse agonists improved coronary flow, reduced arrhythmias, and provided cardioprotection from ischemia-reperfusion injury, an effect that was due, at least in part, to decreased cardiomyocyte apoptosis. Participation of Mas in ischemia-reperfusion injury was confirmed in Mas knockout mice, which had reduced infarct size relative to mice with normal Mas expression. These results suggest that activation of Mas during myocardial infarction contributes to ischemia-reperfusion injury and further suggest that inhibition of Mas-G(q) signaling may provide a new therapeutic strategy directed at cardioprotection.
Similar articles
- SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Strande JL, et al. Basic Res Cardiol. 2007 Jul;102(4):350-8. doi: 10.1007/s00395-007-0653-4. Epub 2007 Apr 30. Basic Res Cardiol. 2007. PMID: 17468933 Free PMC article. - Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury.
Strande JL, Widlansky ME, Tsopanoglou NE, Su J, Wang J, Hsu A, Routhu KV, Baker JE. Strande JL, et al. Cardiovasc Res. 2009 Jul 15;83(2):325-34. doi: 10.1093/cvr/cvp122. Epub 2009 Apr 20. Cardiovasc Res. 2009. PMID: 19380418 Free PMC article. - NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury.
Sun Z, Tong G, Ma N, Li J, Li X, Li S, Zhou J, Xiong L, Cao F, Yao L, Wang H, Shen L. Sun Z, et al. Basic Res Cardiol. 2013 May;108(3):341. doi: 10.1007/s00395-013-0341-5. Epub 2013 Mar 6. Basic Res Cardiol. 2013. PMID: 23463182 - The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection.
Hausenloy DJ, Chilian W, Crea F, Davidson SM, Ferdinandy P, Garcia-Dorado D, van Royen N, Schulz R, Heusch G. Hausenloy DJ, et al. Cardiovasc Res. 2019 Jun 1;115(7):1143-1155. doi: 10.1093/cvr/cvy286. Cardiovasc Res. 2019. PMID: 30428011 Free PMC article. Review. - The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury.
Dragasevic N, Jakovljevic V, Zivkovic V, Draginic N, Andjic M, Bolevich S, Jovic S. Dragasevic N, et al. Can J Physiol Pharmacol. 2021 Jan;99(1):18-29. doi: 10.1139/cjpp-2020-0276. Epub 2020 Aug 15. Can J Physiol Pharmacol. 2021. PMID: 32799671 Review.
Cited by
- International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].
Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, Thomas WG. Karnik SS, et al. Pharmacol Rev. 2015 Oct;67(4):754-819. doi: 10.1124/pr.114.010454. Pharmacol Rev. 2015. PMID: 26315714 Free PMC article. Review. - Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice.
Peña Silva RA, Kung DK, Mitchell IJ, Alenina N, Bader M, Santos RA, Faraci FM, Heistad DD, Hasan DM. Peña Silva RA, et al. Hypertension. 2014 Aug;64(2):362-8. doi: 10.1161/HYPERTENSIONAHA.114.03415. Epub 2014 May 5. Hypertension. 2014. PMID: 24799613 Free PMC article. - Connective tissue growth factor dependent collagen gene expression induced by MAS agonist AR234960 in human cardiac fibroblasts.
Chatterjee A, Barnard J, Moravec C, Desnoyer R, Tirupula K, Karnik SS. Chatterjee A, et al. PLoS One. 2017 Dec 29;12(12):e0190217. doi: 10.1371/journal.pone.0190217. eCollection 2017. PLoS One. 2017. PMID: 29287092 Free PMC article. - The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Li XC, Zhang J, Zhuo JL. Li XC, et al. Pharmacol Res. 2017 Nov;125(Pt A):21-38. doi: 10.1016/j.phrs.2017.06.005. Epub 2017 Jun 12. Pharmacol Res. 2017. PMID: 28619367 Free PMC article. Review. - Atypical signaling and functional desensitization response of MAS receptor to peptide ligands.
Tirupula KC, Desnoyer R, Speth RC, Karnik SS. Tirupula KC, et al. PLoS One. 2014 Jul 28;9(7):e103520. doi: 10.1371/journal.pone.0103520. eCollection 2014. PLoS One. 2014. PMID: 25068582 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases